News Overview

Pharmatec Advances Downstream Process Development (DSP) in Biotech Production

For 2010, sales of 100 billion USD are forecasted.1 Such increases have triggered a growing demand for adequate production capacity. Rentschler Biotechnologie, based in Laupheim, Germany, has been developing and producing biopharmaceuticals for clinical studies and market supply for over 30 years. The company‘s portfolio includes development and GMP production of protein drugs from cell cultures in fermenters or stirred reactors. For years, Rentschler has been continuously investing in new machinery, achieving a six-fold increase in its production capacity, and it now has nine independent GMP production lines with operating volumes between 30 and 2,500 liters.

Download PDF (1,6 MB)

For more information please contact:

Mike Müller
Phone +7 499 176 9258
mike.mueller1@bosch.com

back to the overview